MBX Biosciences (MBX) Common Equity (2023 - 2026)

MBX Biosciences has reported Common Equity for 4 years, with the latest figure at $437.8 million in Q1 2026.

• Quarterly Common Equity rose 85.95% year-over-year to $437.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $437.8 million (up 85.95% YoY) and the FY2025 annual result came in at $369.2 million, up 43.42% from the prior year.
• Common Equity improved to $437.8 million in Q1 2026 per MBX's latest filing, from $369.2 million in the prior quarter.
• Over five years, Common Equity peaked at $437.8 million in Q1 2026 and troughed at -$97.9 million in Q2 2024.
• A 4-year average of $169.1 million and a median of $235.4 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity soared 518.66% in 2024, then jumped 42.81% in 2025.
• Over 4 years, Common Equity stood at -$72.5 million in 2023, then soared by 455.25% to $257.4 million in 2024, then jumped by 43.42% to $369.2 million in 2025, then gained by 18.56% to $437.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $437.8 million, $369.2 million, and $387.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.